Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

[1] Daver N(2019)Targeting FLT3 mutations in AML: review of current knowledge and evidence Leukemia 33 299-312

[2] Schlenk RF(2013)FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Prog 2013 220-226

[3] Russell NH(2002)Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy Leukemia 16 1699-1704

[4] Levis MJ(2010)Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse Leuk Res 34 752-756

[5] Levis M(2018)Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial Lancet Oncol 19 889-903

[6] Boissel N(2018)Phase 2b study of 2 dosing regimens of quizartinib monotherapy in Blood 132 598-607

[7] Cayuela JM(2017)-ITD-mutated, relapsed or refractory AML Xenobiotica 47 856-869

[8] Preudhomme C(2013)An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia J Clin Oncol 31 3681-3687

[9] Thomas X(2019)Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status Br J Clin Pharmacol 85 2108-2117

[10] Grardel N(2019)Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite Lancet Oncol 20 984-997

[1] Daver N(2019)Targeting FLT3 mutations in AML: review of current knowledge and evidence Leukemia 33 299-312

[2] Schlenk RF(2013)FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Prog 2013 220-226

[3] Russell NH(2002)Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy Leukemia 16 1699-1704

[4] Levis MJ(2010)Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse Leuk Res 34 752-756

[5] Levis M(2018)Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial Lancet Oncol 19 889-903

[6] Boissel N(2018)Phase 2b study of 2 dosing regimens of quizartinib monotherapy in Blood 132 598-607

[7] Cayuela JM(2017)-ITD-mutated, relapsed or refractory AML Xenobiotica 47 856-869

[8] Preudhomme C(2013)An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia J Clin Oncol 31 3681-3687

[9] Thomas X(2019)Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status Br J Clin Pharmacol 85 2108-2117

[10] Grardel N(2019)Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite Lancet Oncol 20 984-997